Improving treatment for multidrug-resistant tuberculosis
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods
This study is looking at new medicines for people with multidrug-resistant tuberculosis (MDR-TB) to find better and safer ways to treat the disease, so patients can get well faster and with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10829824 on NIH RePORTER |
What this research studies
This research focuses on enhancing treatment regimens for patients suffering from multidrug-resistant tuberculosis (MDR-TB) by utilizing improved epidemiologic methods. The project aims to evaluate the effectiveness of new TB drugs, such as bedaquiline and delamanid, and to establish optimal treatment protocols that are less toxic and more effective than traditional methods. By analyzing data from clinical trials and existing treatment outcomes, the research seeks to provide clearer guidelines for healthcare providers managing MDR-TB cases. Patients may benefit from more effective treatment options that could lead to higher cure rates and shorter treatment durations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multidrug-resistant tuberculosis who require treatment.
Not a fit: Patients with drug-sensitive tuberculosis or those who do not have tuberculosis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with multidrug-resistant tuberculosis.
How similar studies have performed: Previous research has shown promise in improving treatment regimens for tuberculosis, particularly with the introduction of new drugs, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Franke, Molly Forrest — Harvard Medical School
- Study coordinator: Franke, Molly Forrest
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.